Daiichi Pharmaceuticals clinical trials
Acquired by Daiichi Sankyo, Sep 28, 2005 · source ↗
The registry lists 6 studies whose lead sponsor is Daiichi Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 10, 2013.
Before and after it joined Daiichi Sankyo
- First submitted before Daiichi Pharmaceuticals became part of Daiichi Sankyo
- 6
- First submitted after Daiichi Pharmaceuticals became part of Daiichi Sankyo
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 5
- Withdrawn
- 1
Registry sponsor names on this page
- Daiichi Pharmaceuticals6 studies
Something wrong with this grouping? Tell us on the Daiichi Sankyo page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Daiichi Sankyo studies →
- DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00005091Phase 2
Sponsor listed in the registry: Daiichi Pharmaceuticals · First submitted before Daiichi Pharmaceuticals became part of Daiichi Sankyo
- Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid TumorsWithdrawnNCT00072228Phase 1
Sponsor listed in the registry: Daiichi Pharmaceuticals · First submitted before Daiichi Pharmaceuticals became part of Daiichi Sankyo
- A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.CompletedNCT00002138Phase 1
Sponsor listed in the registry: Daiichi Pharmaceuticals · First submitted before Daiichi Pharmaceuticals became part of Daiichi Sankyo
- A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 DaysCompletedNCT00002136Phase 1
Sponsor listed in the registry: Daiichi Pharmaceuticals · First submitted before Daiichi Pharmaceuticals became part of Daiichi Sankyo
- A Study of Tecogalan SodiumCompletedNCT00002342Phase 1
Sponsor listed in the registry: Daiichi Pharmaceuticals · First submitted before Daiichi Pharmaceuticals became part of Daiichi Sankyo
- A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4CompletedNCT00002137Phase 1
Sponsor listed in the registry: Daiichi Pharmaceuticals · First submitted before Daiichi Pharmaceuticals became part of Daiichi Sankyo